IN8BIO, INC. current report, 01 May 2023

Full document

IN8bio, Inc. Form 8-K Summary

Business Context and Reporting Period

IN8bio, Inc. filed a Current Report on Form 8-K dated May 1, 2023, under Item 5.02. The filing reports a change in the company’s board of directors; it does not present quarterly or annual financial results.

Material Corporate Event

  • The board increased its size from six to seven directors.
  • Jeremy Graff, Ph.D., was appointed as a Class I director, with a term expiring at the 2025 annual meeting of stockholders.
  • Dr. Graff was appointed to the Nominating and Corporate Governance Committee and as chairperson of the Science and Technology Committee.
  • Dr. Graff is the Chief Scientific Officer of IMV, Inc. and has prior oncology and biotechnology executive experience.

Compensation, Indemnification, and Related-Party Matters

  • Dr. Graff will receive compensation consistent with the company’s non-employee director compensation policy.
  • The company entered into its standard director indemnification agreement with Dr. Graff, which may require indemnification for certain expenses, judgments, fines, and settlement amounts arising from his service as a director.
  • The filing states that there were no arrangements or understandings supporting his selection as a director and no relationships or transactions requiring disclosure under Item 404(a) of Regulation S-K.

Financial Metrics, Guidance, and Risks

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or an operating outlook. It also does not identify new financial contingencies or unusual financial items beyond the potential obligations under the director indemnification agreement.

Important Facts for Investors to Verify

  • Dr. Graff’s role and responsibilities on the board’s committees.
  • The applicable non-employee director compensation policy and any equity awards or other compensation disclosed in related company filings.
  • The terms and scope of the indemnification agreement.
  • Subsequent filings for any changes to board composition, committee assignments, or director compensation.